Status:
RECRUITING
A Clinical Study Aims to Assess the Consistency of Clinical Efficacy in Colorectal Cancer Treatment and Drug Susceptibility Outcomes Using a Novel Drug Susceptibility Testing Method
Lead Sponsor:
Funan Liu
Collaborating Sponsors:
Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences
Precedo Pharmaceuticals Co. Ltd.
Conditions:
Colorectal Cancer
Organoids
Eligibility:
All Genders
18-80 years
Brief Summary
The study is a real-world observational clinical study. Patients diagnosed as colorectal cancer through histopathology were screened and enrolled. Before anti-tumor treatment, colonoscopy biopsy tissu...
Eligibility Criteria
Inclusion
- Male or female, aged ≥ 18 and ≤80;
- Patients with colorectal cancer diagnosed by histopathology;
- Patients who need neoadjuvant treatment; adjuvant therapy after radical surgery or palliative treatment;
- Fresh tumor tissue specimens or malignant pleural effusion or ascites can be obtained;
- Patients who sign the informed consent form, and are able to comply with the study period treatment process.
Exclusion
- Inability to follow the research protocol;
- Inability to obtain relevant fresh specimens by biopsy/surgery/puncture;
- Concomitant contraindications to chemotherapy;
- pregnant or lactating women;
- Patients deemed inappropriate by investigators.
Key Trial Info
Start Date :
October 18 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT06100016
Start Date
October 18 2023
End Date
December 1 2025
Last Update
February 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Phase I Clinical Trials Center Of The First Hospital of China Medical University
Shenyang, Liaoning, China, 110001